Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

PARP Inhibitors in BRCA1/2-mutated Patients in Prostate Cancer

December 1st 2016

Identifying Bone Progression in Metastatic Prostate Cancer and Treatment Options

December 1st 2016

Immunotherapy and the Abscopal Effect in Treating Metastatic Prostate Cancer

December 1st 2016

Radium-223 Alone and with Other Agents for Prostate Cancer

December 1st 2016

FDA-approved Indications for Treatment Versus Use in Current Clinical Trials

December 1st 2016

Clinical Trials in Nonmetastatic Castration-Resistant Prostate Cancer

December 1st 2016

Challenges in Treating Nonmetastatic Castration-Resistant Prostate Cancer

December 1st 2016

Decisions on Choosing LHRH Agonists for Treating Prostate Cancer

December 1st 2016

Use of LHRH Agonists Versus Antagonists in Prostate Cancer

December 1st 2016

Multidisciplinary Approach and Role of PSA and Testosterone Monitoring in Prostate Cancer

December 1st 2016

Intermittent versus Continuous Androgen-Deprivation Therapy in Prostate Cancer

December 1st 2016

Advanced Imaging Techniques for Prostate Cancer

December 1st 2016

Triggers to Initiate Androgen-Deprivation Therapy (ADT) in Prostate Cancer

December 1st 2016

Dr. Bryan Mehlhaff on PSA's Role in Prostate Cancer

November 29th 2016

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the controversy surrounding prostate-specific antigen (PSA) testing in prostate cancer.

Dr. Rathkopf on Investigative Agents in Prostate Cancer

November 28th 2016

Dana E. Rathkopf, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses agents being explored as treatments for patients with prostate cancer, including apalutamide and PARP inhibitors.

Dr. Sandler on Chemotherapy Combination Regimens in Prostate Cancer

November 28th 2016

Howard M. Sandler, MD, chair, Department of Radiation Oncology, professor of Radiation Oncology, Cedars-Sinai Medical Center, discusses potential combination regimens with chemotherapy as treatment for patients with prostate cancer.

Dr. Oh on the Role of Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

November 23rd 2016

William K. Oh, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses the role of docetaxel in the treatment of patients with metastatic hormone-sensitive prostate cancer.

New Imaging Strategies for Prostate Cancer Explored

November 23rd 2016

Continuing research will have to evaluate whether combining serum biomarkers or other measurable clinical factors with multiparametric magnetic resonance imaging results can help make negative or inaccurate prostate biopsies a rarity rather than the norm.

Expert Discusses the Future of Circulating Biomarkers in Prostate Cancer

November 23rd 2016

Biomarkers play a key role in the optimization of treatments for patients with prostate cancer. According to Mark Stein, MD, they can even serve as clinical endpoints in trials.

Looming Questions, Challenges Facing Physicians in Prostate Cancer

November 22nd 2016

Identifying biomarkers to determine who should receive chemotherapy, targeted agents, and immunotherapy is just one of several obstacles the prostate cancer community is currently facing.